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Objectives This study sought to validate the sensitivity and speciﬁcity of the Academic Research
Consortium’s (ARC) classiﬁcation of stent thrombosis.
Background Classiﬁcation of stent thrombosis according to ARC criteria has become widely ac-
epted. The criteria have not been validated against an autopsy standard.
ethods An autopsy registry of 139 subjects with prior coronary stenting underwent detailed histo-
athological analysis to assess for stent thrombosis. Based on clinical data only, cases were adjudi-
ated according to ARC stent thrombosis criteria, including a proposed modiﬁcation of the possible
lassiﬁcation to include death beyond 30 days due only to sudden death or acute ischemia.
esults Autopsy results conﬁrmed 51 cases as positive and 88 as negative for stent thrombosis.
linical adjudication classiﬁed 105 cases as deﬁnite (10), probable (31), or possible (64) ARC stent
hrombosis. Speciﬁcity was high for deﬁnite (99%) and deﬁnite plus probable (83%) criteria, but sen-
itivity was poor at 18% and 51%, respectively. Including the possible cases improved sensitivity to
2% but reduced speciﬁcity to 34% (58 false positives). The modiﬁed possible criteria eliminated
3 false positive cases (speciﬁcity  49%) and was the best approximation of a hypothetical gold
standard in a sensitivity analysis if late death represented at least 20% of all stent thrombosis cases.
Conclusions In a selected autopsy sample, restricting ARC stent thrombosis to deﬁnite or deﬁnite
plus probable criteria results in substantial under-reporting of conﬁrmed cases. Inclusion of a modi-
ﬁed possible classiﬁcation may provide the best estimate of late and very late stent thrombosis
rates. (J Am Coll Cardiol Intv 2011;4:554–9) © 2011 by the American College of Cardiology
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555Stent thrombosis is a catastrophic complication of coronary
stenting, presenting as sudden death or nonfatal myocardial
infarction (MI) in almost all cases (1,2). After a controversy
urrounding possible inconsistent and incomplete reporting
f stent thrombosis in drug-eluting stent (DES) trials,
specially those events occurring more than 1 year after
tenting (3), the Academic Research Consortium (ARC)
roposed a standardized classification (4). This classification
tandardized the inconsistencies of previous trial protocol
efinitions, by including uniform criteria for angiographic
onfirmation, allowing for inclusion of probable events
resenting as new acute myocardial infarction without
ngiographic confirmation, and maintaining the principle of
ntention-to-treat by not excluding patients with interval
arget lesion revascularization. Concern remained, however,
urrounding those events occurring beyond 1 year that may
resent as unexplained death. Although these events were
onsidered as possible stent thrombosis by ARC, it became
ecognized that an increasing proportion of deaths remain
nexplained over time, leading to a potential exaggeration of
he rates of very late stent thrombosis as well as possible
ilution of a signal for differences between groups if events
ther than stent thrombosis were included in a substantial
umber (5,6). For these reasons, most studies have restricted
he definition of cases to those meeting definite or probable
riteria, and thereby have not accounted for the vast majority of
ases presenting as late death (7,8).
Although the ARC classification has been accepted and
ecommended as a standard for determining stent throm-
osis, it has not been validated for the adjudication of death
vents. We sought to apply the ARC classification for
djudication of stent thrombosis based on symptomatology
mmediately before death and other clinical data among
ubjects who had died after prior stent implantation and had
een selected for detailed autopsy analysis of the stented
oronary segments.
ethods
Patients and lesions. From the CVPath registry of autopsies
ith coronary stents, 139 consecutive patients referred
etween June 2002 and March 2008 and who received at
east 1 DES were examined. The study cohort included only
irolimus-eluting or paclitaxel-eluting DES. Cases were
outinely referred to CVPath Institute, Inc. (Gaithersburg,
aryland) from the local medical examiners when the
atients had received coronary stents. Cases from other
nstitutions were referred to CVPath Institute, Inc. when
he pathologist was unable to section the coronary artery
ith the stent intact. Causes of death were reported as
tent-related cardiac deaths, nonstent-related cardiac
eaths, and non-cardiac deaths as previously defined (9).
riefly, cardiac death was determined after a complete
utopsy, including examination of the myocardium. Theresence of an occlusive luminal thrombus or nonocclusive
hrombus with distal embolization was considered a stent-
elated cardiac death. The presence of acute thrombus was
efined as a platelet-rich thrombus that occupied 30% of
he cross-sectional area of the lumen. Nonstent-related
ardiac deaths were defined if the stent was patent without
vidence of thrombus or restenosis (luminal stenosis 75%
ross-sectional area) but other cardiac causes were likely,
ncluding other coronary artery disease with severe narrow-
ng (75% cross-sectional area stenosis) of 1 or more major
oronary arteries, presence of prior myocardial infarction
nd history consistent with arrhythmia, or other myocardial
r valvular heart disease that was deemed responsible for the
eath.
Event adjudication. Available clinical data including any
etails related to the previous stent procedure and relevant
ardiac and other medical history leading up to the time of
eath were compiled for review by a clinical events com-
ittee (CEC). These data included pre-morbid electrocar-
iography, hospital discharge summary, and report of cor-
nary angiography if performed, but the CEC did not have
ccess to actual angiograms. The CEC was not aware of any
nformation from the autopsy
tudy.
The clinical data summary
nd a standard adjudication case
eport form were sent to each of
reviewers. The reviewers were
sked to determine cause of
eath as cardiac versus noncar-
iac, and in cases of cardiac
eath, they were asked if the
linical data were consistent with ARC definite, probable,
r possible stent thrombosis. If there was concordance for all
spects of the adjudication, this result was entered into the
vent database. If there was discordance, the event was
eviewed by the full CEC panel for consensus and this
ecision was then entered into the database. All adjudica-
ions were patient-based. If 1 stent had been implanted,
hen stent thrombosis for any stent was considered as a
onfirmed case. If 1 stent thrombosis was confirmed for a
atient, then the case with the highest ARC level of
ertainty was adjudicated.
Adjudicated endpoint deﬁnitions. The CEC determined
cardiac death as any death related to cardiac diagnosis or
occurring because of a complication from a cardiac proce-
dure. Any other death for which a clear noncardiac cause
was not identified was also considered as cardiac. MI was
defined as any event with acute ischemic signs or symptoms
and associated with any elevation of creatine kinase-
myocardial band or troponin. MI was attributed to the
target vessel unless a non-target vessel could be clearly
implicated by electrocardiography or angiography. Stent
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
CEC  clinical events
committee
DES  drug-eluting stent(s)
MI  myocardial infarctionthrombosis was defined according to the ARC classification
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556except that cases adjudicated as possible were also further
subclassified as either: 1) sudden cardiac death or acute
ischemia likely; or 2) unexplained death, acute ischemia
unlikely (Table 1). A new category termed “ARC modified
possible” included only those cases classified as sudden
death or acute ischemia likely. ARC definite stent throm-
bosis required angiographic report of thrombus or occlusion
and clinical report consistent with acute coronary syndrome.
Statistical analysis. Stent thrombosis was classified accord-
ing to CEC adjudication as definite, definite or probable,
any ARC (definite, probable, or possible), or any ARC
modified (definite, probable, or modified possible). The
autopsy confirmation of stent thrombosis was considered as
a true positive diagnosis and the absence of stent thrombosis
by autopsy was considered as a true negative. Sensitivity was
calculated for each category of stent thrombosis as the
number of autopsy-confirmed cases that were adjudicated as
confirmed cases divided by total number of autopsy-
confirmed cases. Specificity was calculated for each category
of stent thrombosis as the number of cases that were not
confirmed as stent thrombosis by autopsy and were adjudi-
cated as not being stent thrombosis divided by the total
number of cases not confirmed as stent thrombosis by
autopsy.
The time-to-death was calculated based on time from
most recent stent procedure. The time-to-stent-thrombosis
was calculated as time from most recent stent procedure
unless prior specific stent other than most recent was
identified as thrombotic. Time-to-stent-thrombosis could
not be determined specifically for 3 cases that were pre-
sumed to be beyond 30 days and within 1 year, that is, late
stent thrombosis. Results for time-to-event are presented as
median and interquartile range.
We performed a simulated sensitivity analysis based on a
hypothetical sample of 10,000 patients with variable pro-
portion of stent thrombosis events presenting as late death,
using the calculated sensitivity and specificity for possible
and modified possible criteria from this study when stent
thrombosis presented as late death and assuming 90%
Table 1. ARC Classification of Stent Thrombosis Plus
Proposed Modified Possible Criteria
Classification Criteria
Deﬁnite Acute coronary syndrome with angiographic or
pathological conﬁrmation of thrombus
Probable Unexplained death within 30 days or MI involving target
vessel territory without angiographic conﬁrmation
Possible Any unexplained death beyond 30 days
Possible (modiﬁed) Any unexplained death beyond 30 days where sudden
cardiac death or acute ischemic event is likely
ARC Academic Research Consortium; MImyocardial infarction.sensitivity and 99% specificity for definite and probablecriteria when stent thrombosis events did not present as late
death.
Results
Autopsy ﬁndings. There were 139 cases referred for au-
topsy. Of these, cardiac death was confirmed in 111 (80%)
cases. The median time-to-cardiac-death was 115 days
(interquartile range 6 to 366). Among the cardiac deaths,
stent thrombosis was confirmed in 51 (45%) cases, including
37 occlusive and 13 nonocclusive thrombi. Other causes of
death are shown in Table 2. Of 12 subjects with analyzable
stents in 1 vessel, thrombosis was present in 1 location
n 8 subjects. There were 3 stent thrombosis cases that had
ES and bare-metal stents in different locations with
hrombosis of DES only in 1 subject, of bare-metal stent
nly in 1 subject, and of both DES and bare-metal stent in
he other. The median time-to-stent-thrombosis was 51
ays (interquartile range: 12 to 260 days). The timing of
onfirmed stent thrombosis was early in 21 cases, late in 22
ases, and very late in 8 cases. Stent thrombosis involved the
eft main in 3 cases, left anterior descending artery in 28
ases, circumflex artery in 13 cases, right coronary artery in
2 cases, left internal mammary artery bypass graft in 1 case,
nd a saphenous vein bypass graft in 1 case.
Clinical event committee adjudication. The CEC adjudi-
cated any ARC stent thrombosis in 105 (76%) patients from
this autopsy population. Sensitivity and specificity for each
ARC level of classification according to timing of suspected
stent thrombosis are shown in Table 3. ARC definite or
probable stent thrombosis identified stent thrombosis asso-
Table 2. Causes of Death Reported by Autopsy (n  139)
Cardiac causes 111
Stent thrombosis 51 (46)
Diffuse CAD 20 (18)
Healed MI 15 (14)
Acute MI or plaque rupture (not stent-related) 7 (6)
Cardiac procedure complication 6 (5)
Cardiogenic shock 5 (4)
Congestive heart failure 5 (4)
Cardiac rupture after MI 2 (2)
Noncardiac causes 28
Trauma, accidents, suicide 13 (46)
Drug overdose 3 (11)
Bleeding complications 3 (11)
Vascular complications 2 (7)
Pulmonary embolism 2 (7)
Chronic pulmonary disease 2 (7)
Stroke 1 (4)
Sepsis 1 (4)
Diabetic ketoacidosis 1 (4)
Values are n and n (%).CAD coronary artery disease; MImyocardial infarction.
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557ciated with death slightly over 50% of the time. This was
substantially improved (92%) when the possible classifica-
tion was also included, but at a cost of reducing specificity
from nearly 100% for ARC definite or 83% for definite or
probable stent thrombosis to 34% for any ARC stent
thrombosis. The 4 cases that were not identified by any
ARC classification are described in Table 4.
Application of the modified possible criteria resulted in
improved specificity over the current ARC possible criteria,
with 13 fewer false positive cases, but did fail to detect stent
thrombosis in an additional 2 cases. This included 1 subject
who died 353 days after stenting with reported cause of
sepsis in the clinical record and 1 subject who died 979 days
after stenting with clinical report of being found after an
alcohol-related fall and apparent head trauma. Despite
improved specificity, ARC modified possible criteria con-
tinued to overdiagnose stent thrombosis in 45 of 88 cases
(Table 5).
Sensitivity analysis based on prevalence of stent thrombosis
presenting as late death. The impact of the sensitivity and
pecificity of ARC-adjudicated late stent thrombosis de-
ends on the prevalence of late death as a presentation for
Table 3. Results of Sensitivity and Specificity for ARC Stent Thrombosis C
Sensitivity/Specificity Any ARC ST
Overall Adjudicated ST 105 Adjud
Sensitivity 95% CI 47/51 92 (81–98) 9/51
Speciﬁcity 95% CI 30/88 34 (24–45) 87/88
Early ST (30 days) Adjudicated ST 33† Adjud
Sensitivity 95% CI 20/21 95 (76–100) 6/21
Speciﬁcity 95% CI 13/26 50 (30–70) 25/26
Late ST (30 days) Adjudicated ST 72 Adjud
Sensitivity 95% CI 27/30 90 (73–98) 3/30
Speciﬁcity 95% CI 17/62 27 (17–40) 62/62
Sensitivity adjudicated ST/autopsy confirmed ST; specificity adjudicated no ST/autopsy confirm
death where sudden death or acute ischemic event is considered likely. †For early ARC ST, possible
ARC Academic Research Consortium; CI exact confidence interval; NA not applicable; ST
Table 4. Case Summaries of Autopsy Confirmed ST Not Diagnosed by Any
Time Case Summary
6 days Stent for inferior STEMI complicated by no-reﬂow and ﬁnal distal
occlusion. Patient had early VF arrest and died 6 days later.
34 days 1 month after LAD DES admitted with intracerebral bleed secondary to
brain tumor. Aspirin and clopidogrel discontinued. Patient died
4 days later without regaining consciousness.
38 days 1 month after LAD DES admitted with large stroke requiring craniotom
for midline shift. Patient died 4 days later without other information
120 days Repeat angiography for heart failure symptoms 4 months after DES of
RCA and CX showed severe occlusive disease (99% ostial RCA and
CX). Patient died of cardiopulmonary arrest while awaiting CABG.
CABG coronary artery bypass graft; CEC clinical events committee; CX circumflex artery; DESelevation myocardial infarction; VF ventricular fibrillation; other abbreviations as in Table 3.tent thrombosis. Table 6 depicts the results of ARC
efinite or probable stent thrombosis, any ARC stent
hrombosis, and any ARC-modified stent thrombosis com-
ared with a hypothetical gold standard as the proportion of
tent thrombosis cases presenting as late death varies. When
he frequency of stent thrombosis presenting as late death
xceeds 20% of all stent thrombosis events, the ARC-
odified possible criteria provide a better estimate of the
old standard rate.
iscussion
This is the first report to test the validity of the ARC stent
thrombosis definitions in a relatively large number of
autopsy cases. The results demonstrate that the ARC
definition can be applied by experienced investigators to
accurately identify stent thrombosis in this setting, but
that there is large variability in sensitivity and specificity
depending on ARC criteria being applied. Furthermore,
the accuracy of the adjudicated rates depends on the
prevalence of late death as the presenting manifestation
of stent thrombosis.
te Definite or Probable Any ARC Modified*
ST 10 Adjudicated ST 41 Adjudicated ST 90
8–31) 26/51 51 (37–65) 45/51 88 (76–96)
94–100) 73/88 83 (73–90) 43/88 49 (38–60)
ST 7 NA NA
11–52) NA NA
80–100) NA NA
ST 3 Adjudicated ST 8 Adjudicated ST 57
2–26) 6/30 20 (7–39) 25/30 83 (65–94)
(94–100) 60/62 97 (88–100) 30/62 48 (36–61)
T. Sensitivity and specificity data are presented as%. *For ARCmodified, possible ST is limited to late
ry (late death30 days) is not applicable, and any ARC ST includes definite or probable only.
thrombosis.
efinition
Autopsy Findings Comments
Thrombus nonocclusive ARC deﬁnition requires successful procedure before
ST can be adjudicated
Thrombus occlusive Inadequate clinical information at time of death.
CEC adjudicated that death was related to
intracerebral bleed
Thrombus occlusive Inadequate clinical information at time of death.
CEC adjudicated that death was related to large
stroke
Thrombus nonocclusive
RCA stent only
Original clinical scenario and angiography not
consistent with primary thrombosis; possible
subsequent thrombosis not evident in available
clinical data
-eluting stent(s); LAD left anterior descending; RCA right coronary artery; STEMI ST-segmentriteria
Defini
icated
 18 (
 99 (
icated
 29 (
 96 (
icated
 10 (
 100
edno S
categoARC D
y
.
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558At the height of the DES stent thrombosis controversy,
the ARC definitions were welcomed by regulatory agencies
and clinical trialists as a standardized method for defining
stent thrombosis across clinical trials and various stent types.
Such standardization has value for assessment of potential
safety differences between new devices and other therapies
compared with current treatments or alternative strategies.
Despite such standardization, however, defining an event
can only add value if there is adequate sensitivity to detect
true and likely very weak safety signals while avoiding the
introduction of noise that might dilute the signal.
The evaluation of any clinical definition of stent throm-
bosis is hampered by the unavailability of a gold standard—
pathological examination of the stent segment—in most
Table 5. ST by ARC Modified Definition Not Confirmed by Autopsy Findings
ARC Classification and Criteria for Adjudication n
Deﬁnite 1
STEMI and angiographic thrombus reported 1 Patient with che
autopsy did n
Probable 13
Unexplained death within 30 days 10
Sudden death after elective stent 2 Diffuse CAD in 1
Sudden death after acute MI 4 2 cardiac ruptur
Unexplained cause of death 4 2 unreported pr
1 heroin overdo
Target vessel MI without
angiographic conﬁrmation
3 MIs involving no
Possible (modiﬁed) 31
Unexplained sudden death beyond 30 days
with other cause identiﬁed
23 12 diffuse CAD
1 BMS total o
Unexplained sudden death after
noncardiac surgery
2 1 discontinued d
Other unexplained sudden death 6
2 No coronary cau
1 Restenosis with
1 Autopsy reports
and died of h
2 1 diabetic ketoa
BMS bare-metal stent(s); other abbreviations as in Tables 1 and 4.
Table 6. Estimated Accuracy of ARC ST Criteria Acc
% ST Presenting as
Late Death
Gold
Standard %
ARC ST Definite or
(Range
50 3.0 1.6 (1.5–1
40 3.0 1.8 (1.7–2
30 3.0 2.1 (2.0–2
20 3.0 2.3 (2.2–2
Assumptions for hypothetical 10,000 patient population undergoing
points of studypopulation experienceunexplaineddeathbeyond30d
30 days or acute ischemia (estimate from [7,8]); 3) sensitivity for AR
specificity for ARC definite or probable criteria for events other than
classification of late death events from Table 3. *Any ARC definite,
where sudden death or acute ischemic event is considered likely. RanAbbreviations as in Table 3.cases. In our study, detailed pathological evaluation was
performed by a single and experienced pathology group and
provides a gold standard against which to test each of the
ARC criteria. Notably, the highly specific criteria for ARC
definite stent thrombosis detected only 1 case that was not
confirmed by autopsy, but was only present in 18% of
autopsy-confirmed cases. Likewise, the most widely used
ARC classification of definite or probable was falsely posi-
tive in only 17% of unconfirmed cases but present in only
51% of confirmed cases. The lack of sensitivity for definite
and definite or probable criteria was related to the failure to
diagnose stent thrombosis presenting as or resulting in
deaths beyond 30 days. These late deaths represented 30 of
the 51 (59%) confirmed stent thrombosis cases. Concern for
Autopsy Findings and Comments
and ST-segment elevation hours after stent; unsuccessful repeat procedure;
ﬁrm thrombus and noted perforation as cause
no reported cause in 1 case
ardiogenic shock (not reported in clinical data); 1 no cause (suspected cocaine use)
ral complications (1 perforation; 1 dissection with distal stent occlusion);
rogressive heart failure; inadequate clinical data available
t vessel 3; inadequate clinical data to determine MI territory
healed MIs; 2 thrombus nontarget vessels; 2 DES total occlusions;
n
tiplatelet therapy; 1 diffuse CAD and healed MI
ntiﬁed
bus; second DES 6 months earlier for angiographic stent thrombosis
failure as cause; patient had acute event 20 days post-DES without angiography
ilure several weeks later
; 1 cocaine overdose; inadequate clinical data to determine noncardiac cause
to Proportion of ST Presenting as Late Death
ble % Any ARC ST* %
(Range)
Any ARC ST (Modified)* %
(Range)
3.7 (3.3–4.0) 3.3 (3.0–3.7)
3.9 (3.5–4.2) 3.5 (3.3–3.8)
4.2 (3.8–4.4) 3.7 (3.5–4.0)
4.4 (4.0–4.6) 3.8 (3.7–4.2)
y stenting and known ST rate of 3.0% over 5 years: 1) 2.8 percentage
mates from [7,8]); 2) 8%of studypopulation experienceddeathbefore
te or probable criteria for events other than late death is 90%, and
ath is 99%; 4) sensitivity, specificity, and relative frequency for ARC
le, or possible. For any ARC modified, possible is limited to late death
lated based on 95% CI for sensitivity and specificity as in Table 3.st pain
ot con
case;
es; 1 c
ocedu
se; 1 p
ntarge
only; 6
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559failure to account for late and very late stent thrombosis
presenting as death was the basis for including the possible
category in the ARC definition.
Indeed, when the cases of late death that were adjudi-
cated as ARC possible stent thrombosis were included, the
sensitivity improved to 90% in our study, but unfortu-
ately resulted in a false positive diagnosis in 58 of 88 (66%)
ubjects that were not confirmed by autopsy. Such a false
ositive rate more than doubles the estimate of stent
hrombosis and may mask any signal that might be detect-
ble by more specific measures.
We assessed whether the signal-to-noise ratio might be
mproved by inclusion of only those late deaths that sug-
ested a sudden ischemic event. Limiting the ARC possible
riteria to sudden cardiac death or death associated with
robable acute ischemia substantially improved specificity
ith 13 fewer false positives and only reduced sensitivity by
cases. Nevertheless, there remained 45 of 88 (51%) false
ositive diagnoses among this sample.
Study limitations. There are several questions raised by this
nalysis and limitations to be considered. There is obvious
election bias inherent in the autopsy sample. Thus, our
esults only apply to those cases with fatal presentation or
eath early after suspected stent thrombosis. Despite high
atality rates, clinical studies suggest that most cases of stent
hrombosis present with nonfatal acute ischemia (1,2). It is
lso possible that more complete access to clinical data,
ncluding angiography and electrocardiography, in these
ases would improve positive and negative diagnostic accu-
acy. As noted in Tables 4 and 5, inadequate clinical data
nherent in the referral nature of the autopsy cases may have
lso reduced both sensitivity and specificity of the ARC
efinitions. This points to the importance of careful clinical
ollow-up and complete ascertainment of clinical data for
he duration of any clinical study to minimize the uncer-
ainty in determining cause of death.
onclusions
Despite these limitations, the results demonstrate that late
or very late stent thrombosis presenting as death is not
uncommon and that ignoring these events by only reporting
ARC definite or probable stent thrombosis will clearly
underestimate the true frequency of stent thrombosis. Be-
cause most cases likely present with acute ischemia and have
some level of clinical evaluation rather than unexplained late
death, this underestimation is clearly less than suggested by
the 51% sensitivity in our study. Nevertheless, as demon-
strated by sensitivity analysis, as the proportion of stent
thrombosis presenting as late deaths increases, as might be
expected during longer-term follow-up, the accuracy of thedefinite or probable classification decreases. It appears that a
modification of the ARC possible category as was used in
our study offers improved diagnostic accuracy in this setting.
Other modifications to the application of the ARC
criteria may also improve accuracy. As was suggested pre-
viously, removing the inclusion of unexplained death within
30 days after stenting for acute MI may improve diagnostic
accuracy of the ARC probable category (4). In our study, 4
of 13 false positive probable ARC stent thromboses were
related to deaths within 30 deaths after MI.
Finally, our results point to the critical importance of
obtaining autopsy in clinical studies in which accurate
definition of stent thrombosis is a major determinant of
safety. Furthermore, protocol definitions must include the
potential to classify those events presenting as death beyond
30 days. Until there are more accurate clinical criteria
available, we believe the preferred reporting of the ARC
classification should include the modified possible category.
Reprint requests and correspondence: Dr. Donald E. Cutlip,
Cardiovascular Division, Beth Israel Deaconess Medical Center, 330
Brookline Avenue, Boston, Massachusetts 02215. E-mail: dcutlip@
bidmc.harvard.edu.
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